Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
Peter G. Rose, M.D., Stacy Nerenstone, M.D., Mark F. Brady, Ph.D., Daniel Clarke-Pearson, M.D., George Olt, M.D., Stephen C. Rubin, M.D., David H. Moore, M.D., James M. Small, M.D., Ph.D., for the Gynecologic Oncology Group
Background We evaluated the effect of adding secondary cytoreductivesurgery to postoperative chemotherapy on progression-free survivaland overall survival among patients who had advanced ovariancancer and residual tumor exceeding 1 cm in diameter after primarysurgery.
Methods Women were enrolled within six weeks after primary surgery.If, after three cycles of postoperative paclitaxel plus cisplatin,a patient had no evidence of progressive disease, she was randomlyassigned to undergo secondary cytoreductive surgery followedby three more cycles of chemotherapy or three more cycles ofchemotherapy alone.
From Case Western Reserve University and the Division of Gynecologic Oncology, MetroHealth Medical Center both in Cleveland (P.G.R.); the Department of Medicine, University of Connecticut, and Hartford Hospital both in Hartford (S.N.); the Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, N.Y. (M.F.B.); the Division of Gynecologic Oncology, Duke University Medical Center, Durham, N.C. (D.C.-P.); the Division of Gynecologic Oncology, Pennsylvania State University, Hershey Medical Center, Hershey (G.O.); the Division of Gynecologic Oncology, University of Pennsylvania Cancer Center, Philadelphia (S.C.R.); the Division of Gynecologic Oncology, Indiana University School of Medicine, Indianapolis (D.H.M.); and UniPath and Colorado Gynecologic Oncology both in Denver (J.M.S.).
Address reprint requests to Ms. Denise Mackey at the Gynecologic Oncology Group Administrative Office, 4 Penn Center, 1600 JFK Blvd., Suite 1020, Philadelphia, PA 19103.
Havrilesky, L. J., Alvarez Secord, A., Darcy, K. M., Armstrong, D. K., Kulasingam, S.
(2008). Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. JCO
26: 4144-4150
[Abstract][Full Text]
Winter, W. E. III, Maxwell, G. L., Tian, C., Sundborg, M. J., Rose, G. S., Rose, P. G., Rubin, S. C., Muggia, F., McGuire, W. P.
(2008). Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. JCO
26: 83-89
[Abstract][Full Text]
Spriggs, D. R., Brady, M. F., Vaccarello, L., Clarke-Pearson, D. L., Burger, R. A., Mannel, R., Boggess, J. F., Lee, R. B., Hanly, M.
(2007). Phase III Randomized Trial of Intravenous Cisplatin Plus a 24- or 96-Hour Infusion of Paclitaxel in Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. JCO
25: 4466-4471
[Abstract][Full Text]
Markman, M.
(2007). Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action. JCO
25: 4168-4170
[Full Text]
Winter, W. E. III, Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., McGuire, W. P.
(2007). Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. JCO
25: 3621-3627
[Abstract][Full Text]
Darcy, K. M., Tian, C., Reed, E.
(2007). A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. Cancer Res.
67: 4474-4481
[Abstract][Full Text]
Harter, P., du Bois, A., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., Schroder, W., Muenstedt, K., Schmalfeldt, B., Emons, G., Pfisterer, J., Wollschlaeger, K., Meerpohl, H.-G., Breitbach, G.-P., Tanner, B., Sehouli, J., for the Arbeitsgemeinschaft Gynaekologische Onkolo,
(2006). Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann. Surg. Oncol.
13: 1702-1710
[Abstract][Full Text]
Gervais, D. A., Arellano, R. S., Mueller, P. R.
(2006). Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management.. Am. J. Roentgenol.
187: 746-750
[Abstract][Full Text]
Bhoola, S., Hoskins, W. J.
(2006). Diagnosis and management of epithelial ovarian cancer.. Obstet Gynecol
107: 1399-1410
[Abstract][Full Text]
Wenzel, L., Huang, H. Q., Monk, B. J., Rose, P. G., Cella, D.
(2005). Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study. JCO
23: 5605-5612
[Abstract][Full Text]
(2005). Is Second-Look Surgery Useful in Advanced Ovarian Cancer?. JWatch Women's Health
2005: 2-2
[Full Text]
Cannistra, S. A.
(2004). Cancer of the Ovary. NEJM
351: 2519-2529
[Full Text]
Penson, R. T., Sahani, D., Bell, D. A.
(2004). Case 37-2004 - A 52-Year-Old Woman with Postmenopausal Bleeding and a Cystic Ovarian Mass. NEJM
351: 2531-2538
[Full Text]
Thigpen, T.
(2004). The If and When of Surgical Debulking for Ovarian Carcinoma. NEJM
351: 2544-2546
[Full Text]